Rocket Pharmaceuticals monetized a rare regulatory asset, selling an FDA pediatric disease priority review voucher tied to the accelerated approval for Kresladi in March. The company disclosed it received $180 million from the voucher transaction, characterizing the proceeds as non-dilutive capital intended to fund additional pipeline work. In addition to supporting ongoing activities, Rocket said the funding will back a planned gene therapy program for Danon disease that is in pivotal clinical testing. Danon disease is a rare genetic disorder in which timing and trial financing can materially affect the path to registration. The transaction underscores how voucher markets continue to function as a financing lever for mid-to-late stage developers seeking to extend runway without issuing new equity.